Laporan Kasus: Transarterial Chemoembolization (Tace) Sebagai Terapi Pilihan Pada Karsinoma Hepatoselular

Sherly Eva Wijayaningrum, Firman Parulian Sitanggang, Putu Patriawan


Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and occupies the top 10 most cancers in Indonesia. Men are likely to develop HCC, and 90% cases of HCC develop in the background of chronic liver disease, which associates with hepatitis B and C virus infection. There are numerous treatment options for HCC, however in intermediate-advanced stage, palliative treatment such as transarterial chemoembolization (TACE) and systemic chemotherapy are the management of choice. A 51 years old male with HCC based on history, physical examination, radiology and laboratory result was referred to interventional radiology department for TACE consideration. Barcelona Clinic Liver Cancer (BCLC) B was concluded in this patient after thorough evaluation. There was history of hepatitis B infection, ascites, low albumin level, high AFP, and from Abdominal CT Scan with contrast showed large lobulated mass on the right lobe, without evidence of portal vein thrombosis. TACE was eligible and done using mixed of doxorubicin 50 mg and lipiodol, and embolization using gel foam. After 8 weeks CT evaluation was done and showed increase area of tumor necrosis, while tumor size was stable. Necrosis area expansion is the standard used for evaluating this patient which fell into partial response criteria. TACE is a palliative therapy of choice in accordance with BCLC B recommendation. Evaluation of TACE performance is more optimal by assessing the size of necrosis area compared to mass measurement.


TACE; karsinoma hepatoselular; BCLC; radiologi intervensi; CT Scan

Full Text:



Cartier V and Aube C, 2014. Diagnosis of hepatocellular carcinoma, Diagnostic and Interventional Imaging. 95(7–8): 709–719.

Chanyaputhipong J, Low SCA, and Chow PKH, 2011. Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians. International Journal of Hepatology. 2011: 1–13.

Chen CJ, Yang HI, and Iloeje UH, 2009. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 49(55).

Colombo M, 2001. Screening for cancer in viral hepatitis. Clinics in Liver Disease. 5(1): 109–122.

Duseja A, 2014. Staging of Hepatocellular Carcinoma. Journal of Clinical and Experimental Hepatology. 4: S74–S79.

Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ et al, 2009. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable?. Cancer. 115(3): 616–623.

Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H, 2015. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World Journal of Hepatology. 7(3): 406–424.

Lencioni R, Petruzzi P and Crocetti L, 1993. Chemoembolization of Hepatocellular Carcinoma With Doxirubicin-Ethiodol’. Investigative Radiology. 28(12): 1185.

Liapi E and Geschwind JFH, 2011. Transcatheter Arterial chemoembolization for liver cancer: Is it time to distinguish conventional from drug-eluting chemoembolization?’. CardioVascular and Interventional Radiology. 34(1): 37–49.

Miller RP, Tadagavadi RK, Ramesh G, and Reeves WB, 2010. Mechanisms of cisplatin nephrotoxicity. Toxins. 2(11): 2490–2518.

Najmi Varzaneh F, Pandey A, Aliyari Ghasabeh M, Shao N, Khoshpouri P et al, 2018. Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation. European Radiology. 28(7): 3032–3040.

Piscaglia F and Ogasawara S, 2018. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment’. Liver Cancer. 7(1),: 104–119.

Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N et al, 2013. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602’. Upsala Journal of Medical Sciences. 118(1): 16–22.

Sun HL, Ni JY, Jiang XY, Chen D, Chen YT, and Xu LF, 2017. The effect of lipiodol deposition in HCC after TACE on the necrosis range of PMCT. OncoTargets and Therapy. 10: 3835–3842.

Vincenzi B, Di Maio M, Silletta M, D'Onofrio L, Spoto C et al, 2015. Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis. PLoS ONE. 10(7): 1–12.

Zhang YJ, Chen Y, Ahsan H, Lunn RM, Chen SY et al, 2005. Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. Cancer Letters. 221(2): 135–143.

Zhu RX, Seto WK, Lai CL, Yuen MF, 2016. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut and Liver. 10(3): 332–339.



  • There are currently no refbacks.

Copyright (c) 2020 Sherly Eva Wijayaningrum, Firman Parulian Sitanggang, Putu Patriawan

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



Jurnal Ilmiah Kedokteran Wijaya Kusuma 

ISSN: 1978-2071(print); 2580-5967 (online)
Published by the Institute for Research and Community Services (LPPM) of University of Wijaya Kusuma Surabaya.
Surabaya, Indonesia
Creative Commons License
All publications by Jurnal Ilmiah Kedokteran Wijaya Kusuma are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
counter View My Stats